CB -- The implantation of a polymer-free sirolimus-eluting stent (SES) (Yukon-BTX, Translumina) for infrapopliteal peripheral vascular disease results in significant improvements in primary and secondary patency, compared with bare-metal stents (BMS), based on the results of DES-BTK [below the knee] trial, a late breaking clinical trial Sept. 24 at the annual Transcatheter Cardiovascular Therapeutics (TCT) conference.
